THERESA HOWARD: Open Payments
NPI 1023615333 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$608 in 23 payments from 10 companies in 2025. Trend: 2023 $30 · 2024 $97 · 2025 $608
Food & beverage: $608
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation | 7 | $206 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Merck Sharp & Dohme LLC | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| ABBVIE INC. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Merit Medical Systems Inc | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $19 |
Products named: Remodulin, Adempas, Orenitram, LIVTENCITY, JASCAYD, KEYTRUDA, UPTRAVI, EMBLAVEO.
Industry payments across DC — which companies pay providers there.
